Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer
| Autor: | Annette van den Berg, Robert J. Hamilton, Padraig Warde, Aaron R. Hansen, Leendert H. J. Looijenga, Kopika Kuhathaas, Ricardo Leão, Philippe L. Bedard, Eshetu G. Atenafu, Joan Sweet, Lynn Anson-Cartwright, Ad J. M. Gillis, Peter Chung, Martin O'Malley, João Lobo, Michael A.S. Jewett |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Urology 030232 urology & nephrology 03 medical and health sciences 0302 clinical medicine Testicular Neoplasms Internal medicine medicine Adjuvant therapy Biomarkers Tumor Humans Radiology Nuclear Medicine and imaging Prospective cohort study Testicular cancer Testis neoplasm business.industry Seminoma Odds ratio Neoplasms Germ Cell and Embryonal medicine.disease MicroRNAs 030220 oncology & carcinogenesis Biomarker (medicine) Surgery Germ cell tumors Neoplasm Recurrence Local business |
| Zdroj: | European urology oncology. 4(3) |
| ISSN: | 2588-9311 |
| Popis: | Background Optimal management of clinical stage I (CSI) testicular cancer is controversial due to lack of robust prognostic factors; miRNA-371a-3p holds promise as a biomarker, although its clinical utility for identifying patients at risk of relapse is unknown. Objective To explore the association between serum miR-371a-3p and CSI surveillance relapse. Design, setting, and participants Serial banked sera from 151 CSI (101 seminomas and 50 nonseminomatous germ cell tumors [NSGCTs]) samples from our Princess Margaret active surveillance cohort were tested. Outcome measurements and statistical analysis Using the ampTSmiR test, miR-371a-3p was assayed. Multivariate logistic regression was used to assess the association between postorchiectomy miRNA and relapse. Results and limitations Thirty-four (23%) patients relapsed. There was no association between postorchiectomy miR-371a-3p (2.43 vs 2.74, p = 0.31) or percent decline from before to after orchiectomy (95.8% vs 93.1%, p = 0.14) and relapse. After adjustment for clinical prognostic factors, there remained no association between postorchiectomy miR-371a-3p and relapse (seminoma: odds ratio [OR] 1.33, 95% confidence interval [CI] 0.87–2.02, p = 0.18; NSGCT: OR 0.45, 95% CI 0.21–1.00, p = 0.05). Postorchiectomy miR-371a-3p levels rose as the date of miRNA assessment approached relapse. At relapse, serum markers alpha-fetoprotein and human chorionic gonadotropin were normal in 62%; yet, miR-371a-3p was elevated in 32/34 (94.1%). The magnitude of miR-371a-3p elevation at relapse correlated with disease burden (N1/M0 122.5 vs N2-N3/M0: 521.1; p = 0.05). Limitations include small numbers of relapses and variable time points of serum collection. Conclusions In our cohort of CSI testis cancer patients on surveillance, postorchiectomy miR-371a-3p levels were not associated with relapse, suggesting that miR-371a-3p may not be a useful biomarker for guiding adjuvant therapy. Our data suggest that miR-371a-3p holds potential as an early relapse marker and warrants a prospective study, as this may allow a window for less morbid relapse therapy. Patient summary The promising novel blood biomarker for testis cancer miR-371a-3p may not provide information at testicle removal, but serial monitoring may lead to earlier detection of relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect